SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas

Draft scope assessment: unclear. Attached because the study's own record describes locally advanced disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

Number of participants with treatment emergent adverse events

Source null

→

primary · POSTED

Number of participants with dose limiting toxicities (DLTs)

DLT evaluable population

→

secondary · POSTED

Based on review of all data, including safety, tolerability, PK, antitumor activity, and PD effects

Source null

→

secondary · POSTED

Objective response rate per immune response evaluation criteria in solid tumors (iRECIST) for solid tumors

All treated population with solid tumors

→

secondary · POSTED

Number of participants with positive anti-drug antibody (ADA) titer, of those who were ADA negative at baseline

For arms 0.0001 and 0.001 mg/kg of IV SL-279252, there were no subjects who were ADA negative at baseline. For arms 12.0 and 24.0 mg/kg of IV SL-279252, ADA samples were not collected.

→

secondary · POSTED

The Cmax is the maximum observed serum concentration of SL-279252 following single and multiple doses

PK Population - number analyzed may be less than the number of participants in a given cohort if samples were not available for analysis.

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record

trial

release id: clinical-indications-draft-1
disease state id: ds-cervical-cancer-keytruda-qlex-d7d2e489
nct id: NCT03894618
trial label: SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
applicability: unclear
applicability note: Attached because the study's own record describes locally advanced disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full.
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z
provenance class: registry-condition-search
discovery note: Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count: 6
harms Count: 15
qol Count: 0

outcomes

release id
clinical-indications-draft-1
disease state id
ds-cervical-cancer-keytruda-qlex-d7d2e489
nct id
NCT03894618
outcome key
om-0000
source section id
NCT03894618-om-0000
source outcome index
0
endpoint
Safety Profile of SL-279252
endpoint definition
Number of participants with treatment emergent adverse events
time origin
From Day 1 to 90 days after Last Dose of SL-279252
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-cervical-cancer-keytruda-qlex-d7d2e489
nct id
NCT03894618
outcome key
om-0001
source section id
NCT03894618-om-0001
source outcome index
1
endpoint
Maximum Tolerated Dose (MTD) of SL-279252
endpoint definition
Number of participants with dose limiting toxicities (DLTs)
time origin
From Day 1 to Day 21 (Schedule 1) or Day 28 (Schedule 2)
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
DLT evaluable population
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-cervical-cancer-keytruda-qlex-d7d2e489
nct id
NCT03894618
outcome key
om-0002
source section id
NCT03894618-om-0002
source outcome index
2
endpoint
Recommended Phase 2 Dose for SL-279252
endpoint definition
Based on review of all data, including safety, tolerability, PK, antitumor activity, and PD effects
time origin
Approximately 32 months
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-cervical-cancer-keytruda-qlex-d7d2e489
nct id
NCT03894618
outcome key
om-0003
source section id
NCT03894618-om-0003
source outcome index
3
endpoint
Overall Response Rate of SL-279252
endpoint definition
Objective response rate per immune response evaluation criteria in solid tumors (iRECIST) for solid tumors
time origin
Approximately 32 months
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
All treated population with solid tumors
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-cervical-cancer-keytruda-qlex-d7d2e489
nct id
NCT03894618
outcome key
om-0004
source section id
NCT03894618-om-0004
source outcome index
4
endpoint
Immunogenicity to SL-279252
endpoint definition
Number of participants with positive anti-drug antibody (ADA) titer, of those who were ADA negative at baseline
time origin
Approximately 32 months
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
For arms 0.0001 and 0.001 mg/kg of IV SL-279252, there were no subjects who were ADA negative at baseline. For arms 12.0 and 24.0 mg/kg of IV SL-279252, ADA samples were not collected.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-cervical-cancer-keytruda-qlex-d7d2e489
nct id
NCT03894618
outcome key
om-0005
source section id
NCT03894618-om-0005
source outcome index
5
endpoint
Maximum Serum Concentration (Cmax) of SL-279252
endpoint definition
The Cmax is the maximum observed serum concentration of SL-279252 following single and multiple doses
time origin
Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 1 (cycle = 28 days)
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
PK Population - number analyzed may be less than the number of participants in a given cohort if samples were not available for analysis.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

arms

release id
clinical-indications-draft-1
disease state id
ds-cervical-cancer-keytruda-qlex-d7d2e489
nct id
NCT03894618
outcome key
om-0000
arm key
OG000
arm label
SL-279252 (0.0001 mg/kg S1)
regimen
0.0001 mg/kg of IV SL-279252 (Schedule 1)
analyzed count
1
analyzed unit
Participants
is comparator
Source null
source pointer
NCT03894618-om-0000#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-cervical-cancer-keytruda-qlex-d7d2e489
nct id
NCT03894618
outcome key
om-0000
arm key
OG001
arm label
SL-279252 (0.001 mg/kg S1)
regimen
0.001 mg/kg of IV SL-279252 (Schedule 1)
analyzed count
1
analyzed unit
Participants
is comparator
Source null
source pointer
NCT03894618-om-0000#groups/OG001
release id
clinical-indications-draft-1
disease state id
ds-cervical-cancer-keytruda-qlex-d7d2e489
nct id
NCT03894618
outcome key
om-0000
arm key
OG002
arm label
SL-279252 (0.003 mg/kg S1)
regimen
0.003 mg/kg of IV SL-279252 (Schedule 1)
analyzed count
2
analyzed unit
Participants
is comparator
Source null
source pointer
NCT03894618-om-0000#groups/OG002
release id
clinical-indications-draft-1
disease state id
ds-cervical-cancer-keytruda-qlex-d7d2e489
nct id
NCT03894618
outcome key
om-0000
arm key
OG003
arm label
SL-279252 (0.01 mg/kg S1)
regimen
0.01 mg/kg of IV SL-279252 (Schedule 1)
analyzed count
1
analyzed unit
Participants
is comparator
Source null
source pointer
NCT03894618-om-0000#groups/OG003
release id
clinical-indications-draft-1
disease state id
ds-cervical-cancer-keytruda-qlex-d7d2e489
nct id
NCT03894618
outcome key
om-0000
arm key
OG004
arm label
SL-279252 (0.03 mg/kg S1)
regimen
0.03 mg/kg of IV SL-279252 (Schedule 1)
analyzed count
2
analyzed unit
Participants
is comparator
Source null
source pointer
NCT03894618-om-0000#groups/OG004
release id
clinical-indications-draft-1
disease state id
ds-cervical-cancer-keytruda-qlex-d7d2e489
nct id
NCT03894618
outcome key
om-0000
arm key
OG005
arm label
SL-279252 (0.1 mg/kg S1)
regimen
0.1 mg/kg of IV SL-279252 (Schedule 1)
analyzed count
3
analyzed unit
Participants
is comparator
Source null
source pointer
NCT03894618-om-0000#groups/OG005
release id
clinical-indications-draft-1
disease state id
ds-cervical-cancer-keytruda-qlex-d7d2e489
nct id
NCT03894618
outcome key
om-0000
arm key
OG006
arm label
SL-279252 (0.3 mg/kg S1)
regimen
0.3 mg/kg of IV SL-279252 (Schedule 1)
analyzed count
4
analyzed unit
Participants
is comparator
Source null
source pointer
NCT03894618-om-0000#groups/OG006
release id
clinical-indications-draft-1
disease state id
ds-cervical-cancer-keytruda-qlex-d7d2e489
nct id
NCT03894618
outcome key
om-0000
arm key
OG007
arm label
SL-279252 (1.0 mg/kg S1)
regimen
1.0 mg/kg of IV SL-279252 (Schedule 1)
analyzed count
6
analyzed unit
Participants
is comparator
Source null
source pointer
NCT03894618-om-0000#groups/OG007
release id
clinical-indications-draft-1
disease state id
ds-cervical-cancer-keytruda-qlex-d7d2e489
nct id
NCT03894618
outcome key
om-0000
arm key
OG008
arm label
SL-279252 (3.0 mg/kg S1)
regimen
3.0 mg/kg of IV SL-279252 (Schedule 1)
analyzed count
6
analyzed unit
Participants
is comparator
Source null
source pointer
NCT03894618-om-0000#groups/OG008
release id
clinical-indications-draft-1
disease state id
ds-cervical-cancer-keytruda-qlex-d7d2e489
nct id
NCT03894618
outcome key
om-0000
arm key
OG009
arm label
SL-279252 (6.0 mg/kg S1)
regimen
6.0 mg/kg of IV SL-279252 (Schedule 1)
analyzed count
4
analyzed unit
Participants
is comparator
Source null
source pointer
NCT03894618-om-0000#groups/OG009
release id
clinical-indications-draft-1
disease state id
ds-cervical-cancer-keytruda-qlex-d7d2e489
nct id
NCT03894618
outcome key
om-0000
arm key
OG010
arm label
SL-279252 (12.0 mg/kg S1)
regimen
12.0 mg/kg of IV SL-279252 (Schedule 1)
analyzed count
4
analyzed unit
Participants
is comparator
Source null
source pointer
NCT03894618-om-0000#groups/OG010
release id
clinical-indications-draft-1
disease state id
ds-cervical-cancer-keytruda-qlex-d7d2e489
nct id
NCT03894618
outcome key
om-0000
arm key
OG011
arm label
SL-279252 (24.0 mg/kg S1)
regimen
24.0 mg/kg of IV SL-279252 (Schedule 1)
analyzed count
2
analyzed unit
Participants
is comparator
Source null
source pointer
NCT03894618-om-0000#groups/OG011

harms

release id
clinical-indications-draft-1
disease state id
ds-cervical-cancer-keytruda-qlex-d7d2e489
nct id
NCT03894618
harm key
EG000
source section id
NCT03894618-ae
event group key
EG000
event group label
SL-279252 (0.0001 mg/kg S1)
serious affected
0
serious at risk
1
other affected
1
other at risk
1
frequency threshold
5
collection period
Subjects were followed continuously for all AEs starting when a subject signed the informed consent form, throughout the course of treatment, and for 90 days after the last dose of study treatment, an average of 17 weeks.
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-cervical-cancer-keytruda-qlex-d7d2e489
nct id
NCT03894618
harm key
EG001
source section id
NCT03894618-ae
event group key
EG001
event group label
SL-279252 (0.001 mg/kg S1)
serious affected
1
serious at risk
1
other affected
1
other at risk
1
frequency threshold
5
collection period
Subjects were followed continuously for all AEs starting when a subject signed the informed consent form, throughout the course of treatment, and for 90 days after the last dose of study treatment, an average of 17 weeks.
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-cervical-cancer-keytruda-qlex-d7d2e489
nct id
NCT03894618
harm key
EG002
source section id
NCT03894618-ae
event group key
EG002
event group label
SL-279252 (0.003 mg/kg S1)
serious affected
0
serious at risk
2
other affected
2
other at risk
2
frequency threshold
5
collection period
Subjects were followed continuously for all AEs starting when a subject signed the informed consent form, throughout the course of treatment, and for 90 days after the last dose of study treatment, an average of 17 weeks.
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-cervical-cancer-keytruda-qlex-d7d2e489
nct id
NCT03894618
harm key
EG003
source section id
NCT03894618-ae
event group key
EG003
event group label
SL-279252 (0.01 mg/kg S1)
serious affected
0
serious at risk
1
other affected
1
other at risk
1
frequency threshold
5
collection period
Subjects were followed continuously for all AEs starting when a subject signed the informed consent form, throughout the course of treatment, and for 90 days after the last dose of study treatment, an average of 17 weeks.
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-cervical-cancer-keytruda-qlex-d7d2e489
nct id
NCT03894618
harm key
EG004
source section id
NCT03894618-ae
event group key
EG004
event group label
SL-279252 (0.03 mg/kg S1)
serious affected
0
serious at risk
2
other affected
2
other at risk
2
frequency threshold
5
collection period
Subjects were followed continuously for all AEs starting when a subject signed the informed consent form, throughout the course of treatment, and for 90 days after the last dose of study treatment, an average of 17 weeks.
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-cervical-cancer-keytruda-qlex-d7d2e489
nct id
NCT03894618
harm key
EG005
source section id
NCT03894618-ae
event group key
EG005
event group label
SL-279252 (0.1 mg/kg S1)
serious affected
1
serious at risk
3
other affected
3
other at risk
3
frequency threshold
5
collection period
Subjects were followed continuously for all AEs starting when a subject signed the informed consent form, throughout the course of treatment, and for 90 days after the last dose of study treatment, an average of 17 weeks.
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-cervical-cancer-keytruda-qlex-d7d2e489
nct id
NCT03894618
harm key
EG006
source section id
NCT03894618-ae
event group key
EG006
event group label
SL-279252 (0.3 mg/kg S1)
serious affected
1
serious at risk
4
other affected
4
other at risk
4
frequency threshold
5
collection period
Subjects were followed continuously for all AEs starting when a subject signed the informed consent form, throughout the course of treatment, and for 90 days after the last dose of study treatment, an average of 17 weeks.
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-cervical-cancer-keytruda-qlex-d7d2e489
nct id
NCT03894618
harm key
EG007
source section id
NCT03894618-ae
event group key
EG007
event group label
SL-279252 (1.0 mg/kg S1)
serious affected
3
serious at risk
6
other affected
4
other at risk
6
frequency threshold
5
collection period
Subjects were followed continuously for all AEs starting when a subject signed the informed consent form, throughout the course of treatment, and for 90 days after the last dose of study treatment, an average of 17 weeks.
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-cervical-cancer-keytruda-qlex-d7d2e489
nct id
NCT03894618
harm key
EG008
source section id
NCT03894618-ae
event group key
EG008
event group label
SL-279252 (3.0 mg/kg S1)
serious affected
1
serious at risk
6
other affected
6
other at risk
6
frequency threshold
5
collection period
Subjects were followed continuously for all AEs starting when a subject signed the informed consent form, throughout the course of treatment, and for 90 days after the last dose of study treatment, an average of 17 weeks.
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-cervical-cancer-keytruda-qlex-d7d2e489
nct id
NCT03894618
harm key
EG009
source section id
NCT03894618-ae
event group key
EG009
event group label
SL-279252 (6.0 mg/kg S1)
serious affected
1
serious at risk
4
other affected
3
other at risk
4
frequency threshold
5
collection period
Subjects were followed continuously for all AEs starting when a subject signed the informed consent form, throughout the course of treatment, and for 90 days after the last dose of study treatment, an average of 17 weeks.
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-cervical-cancer-keytruda-qlex-d7d2e489
nct id
NCT03894618
harm key
EG010
source section id
NCT03894618-ae
event group key
EG010
event group label
SL-279252 (12.0 mg/kg S1)
serious affected
0
serious at risk
4
other affected
4
other at risk
4
frequency threshold
5
collection period
Subjects were followed continuously for all AEs starting when a subject signed the informed consent form, throughout the course of treatment, and for 90 days after the last dose of study treatment, an average of 17 weeks.
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-cervical-cancer-keytruda-qlex-d7d2e489
nct id
NCT03894618
harm key
EG011
source section id
NCT03894618-ae
event group key
EG011
event group label
SL-279252 (24.0 mg/kg S1)
serious affected
1
serious at risk
2
other affected
2
other at risk
2
frequency threshold
5
collection period
Subjects were followed continuously for all AEs starting when a subject signed the informed consent form, throughout the course of treatment, and for 90 days after the last dose of study treatment, an average of 17 weeks.
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

quality of life

setting source links

Preserved source evidence · Not medical advice